A urinary tract infection (UTI) is an infection in any part of the urinary system. Women are at greater risk of developing a urinary tract infection compared to men. Urinary tract infections (UTIs) are usually caused by bacteria from poo entering the urinary tract. Antibiotics usually are the first treatment for urinary tract infections.  Medicines commonly used for simple UTI s include Trimethoprim and sulfamethoxazole (Bactrim, Bactrim DS), Fosfomycin (Monurol), Nitrofurantoin (Macrodantin, Macrobid, and Furadantin), Cephalexin, and Ceftriaxone.

Market Dynamics:

High prevalence of urinary tract infection, increasing prevalence of diabetes and kidney stones, increasing geriatric population, and increase in focus on the development of novel therapeutics are some major factors expected to drive growth of the global urinary tract infection therapeutic market during the forecast period.

In October 2021, Spero Therapeutics Inc. submitted a new drug application (NDA) to the U.S. Food and Drug Administration (USFDA), seeking approval for tebipenem HBr tablets for the treatment of complicated urinary tract infections (cUTI), including pyelonephritis, caused by susceptible microorganisms. Moreover, in September 2021, BDR Pharma launched biapenem for the treatment of patients with intra-abdominal infections, lower respiratory infections, or complicated urinary tract infections.

In July 2020, the U.S. Food and Drug Administration (FDA) approved Recarbrio (imipenem, cilastatin and relebactam), an antibacterial drug product to treat adults with complicated urinary tract infections (cUTI) and complicated intra-abdominal infections (cIAI).

Key features of the study:

• This report provides in-depth analysis of the global urinary tract infection therapeutic market, and provides market size (US$ Billion) and compound annual growth rate (CAGR %) for the forecast period (2025–2032), considering 2024 as the base year.
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players.
• It profiles key players in the global urinary tract infection therapeutic market based on the following parameters such as company highlights, products portfolio, key highlights, financial performance, and strategies.
• Key companies covered as a part of this study include Pfizer, Novartis AG, Cipla Inc., Bayer AG, AstraZeneca, Shionogi & Co. Ltd., and GlaxoSmithKline PLC.
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
• The global urinary tract infection therapeutic market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global urinary tract infection therapeutic market.

Detailed Segmentation:

• Global Urinary Tract Infection Therapeutic Market By Drug:
  • Penicillin and Combinations
  • Quinolones
  • Cephalosporin
  • Azoles and Amphotericin B
  • Nitrofurans
  • Other Drugs
• Global Urinary Tract Infection Therapeutic Market By Indication;
  • Complicated UTI
  • Uncomplicated UTI
  • Other Indications
• Global Urinary Tract Infection Therapeutic Market By Geography:
  • North America
  • Europe
  • Asia-Pacific
  • Middle East and Africa
  • South America
• Company Profiles:
  • Pfizer
  • Novartis AG
  • Cipla Inc.
  • Bayer AG
  • AstraZeneca
  • Shionogi & Co. Ltd.
  • GlaxoSmithKline PLC